GeoPharma to launch desloratadine tablets
This article was originally published in The Tan Sheet
Executive SummaryGeoPharma can commercially launch a generic version of Schering Corp.'s Clarinex desloratadine tablets (5 mg) beginning July 2012, under a settlement agreement with Schering, Sepracor and the University of Massachusetts. "The new product launch may be a prescription or over-the-counter product depending on its status at the time of launch," Largo, Fla.-based GeoPharma notes in a Jan. 20 announcement. The company will have six months of marketing co-exclusivity to sell the allergy relief product. The settlement resolves all Hatch-Waxman litigation related to the desloratadine tablets triggered when GeoPharma filed paragraph IV certification for the product
You may also be interested in...
Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.
Indian pharmaceutical companies will soon be asked to seek a no objection certificate for the export of 12 APIs and their formulations, as the country deals with Chinese raw material supply disruptions on the back of the coronavirus crisis. However, the move is not expected to impact the export quantum for now.